Literature DB >> 10973838

Prospective study correlating fibrinopeptide A, troponin I, myoglobin, and myosin light chain levels with early and late ischemic events in consecutive patients presenting to the emergency department with chest pain.

A Sonel1, B M Sasseen, N Fineberg, N Bang, R L Wilensky.   

Abstract

BACKGROUND: Although thrombus formation plays a major role in acute coronary syndromes, few studies have evaluated a thrombus marker in risk stratification of patients with chest pain. Furthermore, the relation between markers that reflect myocardial injury and thrombus formation that may predict events in a heterogeneous patient population is unknown. This study correlated markers of thrombus and myocardial injury with early and late ischemic events in consecutive patients with chest pain. METHODS AND
RESULTS: Serum troponin I (TnI), myoglobin, and myosin light chain levels were obtained from 247 patients and urinary fibrinopeptide A (FPA) from 178 of the 247. By multivariate analysis, patients with an elevated FPA level were 4.82 times more likely to die or have myocardial infarction, unstable angina, and coronary revascularization at 1 week (P=0.002, 95% CI 1.78, 13.03), whereas those with an elevated TnI (>0.2 ng/mL) were 9.41 times more likely (P<0.001, 95% CI 2.84, 31.17). At 6 months (excluding the index event), an elevated FPA level was an independent predictor of events, with an odds ratio of 9.57 (P<0.001, C1 3.29, 27.8), and was the only marker to predict a shorter event-free survival (P<0.001). The other markers did not independently correlate with cardiac events, although MLC incrementally increased early predictive accuracy in combination with the FPA and TnI.
CONCLUSIONS: Elevated FPA and TnI correlated with cardiac events during the initial week in patients presenting to the Emergency Department with chest pain. FPA predicted adverse events and a shorter event-free survival at 6 months.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10973838     DOI: 10.1161/01.cir.102.10.1107

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

1.  The relative utility of cardiac troponin I, creatine kinase-MBmass, and myosin light chain-1 in the long-term risk stratification of patients with chest pain.

Authors:  Graham S Hillis; Pamela Taggart; Delana Wardlaw; Lorraine Hillis; Ning Zhao; William C Dalsey; Antoinette Mangione
Journal:  Clin Cardiol       Date:  2003-03       Impact factor: 2.882

2.  Cardiac Myosin Promotes Thrombin Generation and Coagulation In Vitro and In Vivo.

Authors:  Jevgenia Zilberman-Rudenko; Hiroshi Deguchi; Meenal Shukla; Yoshimasa Oyama; Jennifer N Orje; Zihan Guo; Tine Wyseure; Laurent O Mosnier; Owen J T McCarty; Zaverio M Ruggeri; Tobias Eckle; John H Griffin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-02-27       Impact factor: 8.311

Review 3.  Novel blood coagulation molecules: Skeletal muscle myosin and cardiac myosin.

Authors:  Hiroshi Deguchi; Shravan Morla; John H Griffin
Journal:  J Thromb Haemost       Date:  2020-10-25       Impact factor: 5.824

Review 4.  [Capillary electrophoresis coupled to mass spectrometry for proteome analysis. An innovative diagnostic method for prostate and bladder cancer].

Authors:  S Wittke; E Schiffer; H W Bauer
Journal:  Urologe A       Date:  2007-07       Impact factor: 0.803

5.  Diagnostic Performance of Coronary Tomography Angiography and Serial Measurements of Sensitive Cardiac Troponin in Patients With Chest Pain and Intermediate Risk for Cardiovascular Events.

Authors:  Alexandre de Matos Soeiro; Bruno Biselli; Tatiana C A T Leal; Aline Siqueira Bossa; Maria Cristina César; Sérgio Jallad; Priscila Gherardi Goldstein; Patrícia Oliveira Guimarães; Carlos Vicente Serrano; Cesar Higa Nomura; Débora Nakamura; Carlos Eduardo Rochitte; Paulo Rogério Soares; Múcio Tavares de Oliveira
Journal:  Arq Bras Cardiol       Date:  2022-05       Impact factor: 2.667

6.  Beckman Access versus the Bayer ACS:180 and the Abbott AxSYM cardiac Troponin-I real-time immunoassays: an observational prospective study.

Authors:  Robert H Baevsky; Rajesh K Kapur; Howard A Smithline
Journal:  BMC Emerg Med       Date:  2004-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.